Naloxone Market: Including Top Companies Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc., INSYS Therapeutics

Increasing launches of new naloxone products in market is expected to be one of the major drivers fueling the global naloxone market growth in the near future. For instance, in November 2015, Adapt Pharma Inc. received the U.S. Food and Drug Administration’s (FDA’s) approval for its Narcan (naloxone HCl) nasal spray 4mg, indicated for emergency treatment of known or suspected opioid overdose. In June 2016, Sandoz Canada, a division of Novartis AG, launched S.O.S. naloxone hydrochloride injection in Canada. In July 2017, Indivior Inc., a subsidiary of Indivior Plc., received marketing authorization (MA) from the French Regulatory Agency, French National Agency for Medicines and Health Products Safety (ANSM), for Nalscue naloxone hydrochloride nasal spray, indicated for emergency treatment of characterized or suspected opioid overdose, in France.


Get PDF Sample Copy of this Report @ www.coherentmarketinsights.com/insight/request-sample/1804

Increasing prevalence of opioid overdosing in key countries such as the U.S. and Canada is expected to increase demand for naloxone and significantly drive global naloxone market’s growth over the forecast period. For instance, according to data published by Centers for Disease Control and Prevention (CDC) in 2018, in the U.S. over 630,000 people died from a drug overdose from 1999 to 2016, and in 2016 around 66% of the 63,600 drug overdose deaths involved an opioid. Furthermore, according to the same source in 2016 the number of deaths involving opioids overdose (which include prescription opioids, heroin, and fentanyl) was five times higher than that in 1999.

Favorable reimbursement scenarios for naloxone products is also expected to boost the adoption of products and fuel the global naloxone market growth. For instance, NARCAN nasal spray, a naloxone intranasal spray provided by ADAPT Pharma Inc., has extensive public and private insurance coverage. ADAPT Pharma Inc., entered into an agreement with major Pharmacy Benefits Managers and insurance companies (including Medicaid) to ensure reasonable and affordable costs to the patient. According to ADAPT Pharma Inc.’s official website around 97% of the U.S. insured lives have access to NARCAN Nasal Spray

Furthermore, global naloxone market growth is also expected to rise due to the collective initiatives by government and private organizations for increasing accessibility of naloxone products for emergency treatment opioid overdose. In 2017, 47 states and Washington, DC in the U.S. expanded access to naloxone through legislation that permits prescriptions to people who are likely to encounter someone who might take drug overdose. In 2017, Ontario government provided naloxone kits to police and fire departments to manage emergency case of opioid overdose. Government offered naloxone kits to all 61 police services and 447 fire departments in the Ontario.

Key players operating in the naloxone market include Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc., INSYS Therapeutics, Inc., Mundipharma International Limited, Kaleo, Inc., and Kern Pharma, S.L.

Report with Discount Available @ www.coherentmarketinsights.com/insight/request-discount/1804

Detailed Segmentation:

Global Naloxone Market, By Strength:
0.4 mg/ml
1mg/ml
0.4mg/0.4ml
4mg/0.1ml and Others
Global Naloxone Market, By Drug Type:
Intranasal
Intramuscular/Subcutaneous
Intravenous
Global Naloxone Market, By Distribution Channel:
Hospitals
Clinics
Retail Pharmacies
Online Pharmacies
Others

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.